OpenEvidence's licensed journal moat

These publisher deals matter because they turn OpenEvidence from a generic medical chatbot into a licensed distribution layer for the journals doctors already trust. In practice, that means a clinician can ask a bedside question and get an answer grounded in full text and journal content from NEJM and JAMA, with newer Wiley and Cochrane content expanding the evidence base further. That trust signal helps explain why content partnerships arrived alongside rapid physician adoption and revenue growth.

• NEJM signed in February 2025 and JAMA signed in June 2025, both as multi year content agreements. Those deals gave OpenEvidence rights to use content from flagship journals that already shape physician decision making, which is a much stronger input than scraping abstracts or relying only on open web sources.
  1 openevidence 2 jamanetwork
• The moat is not just better answers, it is better workflow fit. A doctor using OpenEvidence can stay inside one interface instead of separately searching journal sites, reviews, and reference tools. That makes licensed content function like product infrastructure, similar to how UpToDate turned curated evidence into a paid point of care habit.
  5 sacra 6 sacra 7 sacra
• The risk is that the moat has a real toll. Wiley's March 2026 agreement adds more than 400 journals plus Cochrane reviews, and Wiley disclosed a 5 year deal plus an equity stake. That shows publishers now understand the value of licensing into clinical AI, which can raise OpenEvidence's content costs as it scales.
  3 cochrane 4 cloudfront 8 cochrane 9 openevidence

This is heading toward a market where the winning clinical AI product is the one that bundles trusted licensed evidence, physician traffic, and workflow distribution into the same surface. If OpenEvidence keeps stacking exclusive content and then secures deeper EHR access, its journal partnerships can evolve from a credibility edge into the foundation of a full clinical decision platform.